Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KZR | US
0.00
0.43%
Healthcare
Biotechnology
30/06/2024
30/08/2024
0.60
0.59
0.62
0.59
Kezar Life Sciences Inc. a clinical-stage biotechnology company engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616) a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications including lupus nephritis dermatomyositis and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261 a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
66.5%1 month
57.0%3 months
51.9%6 months
51.4%-
-
0.29
-
-
0.06
-
-
-98.46M
43.82M
43.82M
-
-1.42K
-
-
-51.48
2.37
1.20
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.14
Range3M
0.22
Rel. volume
0.31
Price X volume
59.35K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Rallybio Corporation Common Stock | RLYB | Biotechnology | 1.15 | 47.71M | -3.36% | n/a | 0.35% |
Fortress Biotech Inc | FBIO | Biotechnology | 2.03 | 46.31M | -0.98% | n/a | 494.61% |
LAVA Therapeutics BV | LVTX | Biotechnology | 1.75 | 46.02M | -4.37% | n/a | 14.37% |
Akari Therapeutics Plc | AKTX | Biotechnology | 3.83 | 45.78M | 0.52% | n/a | -27.01% |
CALC | CALC | Biotechnology | 4.17 | 44.83M | -3.02% | n/a | 0.00% |
Aadi Bioscience Inc | AADI | Biotechnology | 1.81 | 44.55M | 3.43% | n/a | 1.34% |
CARM | CARM | Biotechnology | 1.07 | 44.45M | -1.83% | n/a | 0.00% |
Lantern Pharma Inc. | LTRN | Biotechnology | 4.09 | 44.03M | 1.24% | n/a | 0.71% |
Syros Pharmaceuticals Inc | SYRS | Biotechnology | 1.64 | 43.97M | -1.20% | n/a | -954.99% |
PASSAGE BIO INC. | PASG | Biotechnology | 0.7006 | 43.27M | -5.96% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.06 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 0.29 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 51.86 | 76.13 | Lower Risk |
Debt to Equity | - | -2.05 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 43.82M | 4.04B | Emerging |